News | Science Selection May 2014 | Volume 122 | Issue 5
New Confidence: Optimizing Benchmark Dose Modeling to Improve Risk Assessment
Carol Potera, based in Montana, has written for EHP since 1996. She also writes for Microbe, Genetic Engineering News, and the American Journal of Nursing.
Related EHP Article
Benchmark dose (BMD) modeling has been touted as a more accurate method for conducting chemical risk assessments.1 In this issue of EHP, a team of researchers applied BMD modeling to hundreds of chemicals whose health effects are already known in an effort to optimize the approach.2
To calculate the highest safe oral dose of a noncarcinogenic chemical, regulators must first estimate the point-of-departure (POD) dose—that is, the dose below which the chemical does not increase disease risk. This POD is then divided by an uncertainty factor to build in extra safety, resulting in a reference dose. In selecting a POD regulators may use the lower confidence limit of the BMD (a value abbreviated BMDL), or they may use the no-observed-adverse-effect level (NOAEL) obtained from animal experiments.
© Shutterstock; Wignall et al.2; Joseph Tart/Brogan & Partners
Although used since 1954,3 NOAEL studies “are not ideal solutions,” says Ivan Rusyn, a toxicologist at the University of North Carolina at Chapel Hill and coauthor of the new study. Often just a few doses of a test chemical are given for varying times to laboratory animals for toxicity testing, and the NOAEL is equal to one of these doses. “This limits NOAEL data,” Rusyn explains, “because the lowest dose may have been arbitrarily set.”
BMD modeling, on the other hand, uses experimental data as the basis for plotting health outcomes against exposure levels along a continuous dose–response curve. (Because of this, BMD analysis is considered inappropriate for certain data sets, such as those with small dosing groups.) Rusyn says a POD derived through BMD modeling can fall to right or left of the NOAEL POD, depending on the data.
In the current study the authors analyzed 880 dose–response data sets for 352 environmental chemicals considered to be human health hazards. BMDLs and NOAELs, they found, gave somewhat similar results, although BMDLs gave slightly lower values, suggesting that toxicity occurs sooner than predicted by NOAELs. “So the BMDL can be more protective than the NOAEL, based on the chemicals we tested,” says Rusyn. However, this result depended on the database.
Researchers typically calculate a BMDL by focusing on data sets for a single chemical at a time. The U.S. Environmental Protection Agency (EPA) has previously used this time-consuming method to derive BMDLs for use in human health risk assessments.4 Rather than assess each chemical separately, Rusyn and colleagues processed several hundred data sets for different chemicals, including about 40 chemicals previously evaluated by the EPA. The team followed BMD recommendations described in the EPA’s Benchmark Dose Technical Guidance document5 and used free BMDS Wizard software.6
For those chemicals previously tested by the EPA, the BMDL results correlated well. “It gave us confidence that dose–response analyses can be done faster and more efficiently than scrutinizing one chemical at a time,” Rusyn says.
Overall, the results showed that the standardized approach used by the investigators to calculate the BMDL effectively processed toxicological and epidemiological data for chemicals collected from public sources and compiled in diverse databases. The findings suggested that BMDLs can be calculated in a consistent fashion to improve comparisons across exposures and outcomes. And they also yielded clues about the types of data best suited for BMD modeling.
All these observations trends may help to improve the design of future BMD evaluations, and BMD modeling may help to align high-volume output from toxicity screening with the needs of risk assessors, Rusyn predicts. That’s good, because high-throughput in vitro testing is generating huge volumes of new data from hundreds of dose–response data sets on thousands of chemicals.
The researchers “are to be commended for undertaking a comprehensive and insightful analysis of a large database comprised of data-rich chemicals and suggesting a viable approach to standardizing the process for determining BMDLs,” says Daniel Krewski, director of the McLaughlin Centre for Population Health Risk Assessment at the University of Ottawa. This standardized approach to determining a POD in support of risk management decisions should be “more efficient, objective, and transparent than current methods,” Krewski says.
However, the approach does not yield PODs for all data sets considered, notes Krewski. And he points out that expert scientific judgment will still be required to convert a POD to a reference dose.
1. Crump KS. A new method for determining allowable daily intakes. Fundam Appl Toxicol 4(5):854–871 (1984); http://www.ncbi.nlm.nih.gov/pubmed/6510615.
2. Wignall JA, et al. Standardizing benchmark dose calculations to improve science-based decisions in human health assessments. Environ Health Perspect 122(5):506–512 (2014); http://dx.doi.org/10.1289/ehp.1307539.
4. EPA. Human Health Benchmarks for Pesticides [website]. Washington, DC:Office of Pesticide Programs, U.S. Environmental Protection Agency (updated 8 April 2013). Available: http://iaspub.epa.gov/apex/pesticides/f?p=HHBP:home [accessed 8 April 2014].
5. EPA. Benchmark Dose Technical Guidance [website]. Washington, DC:Office of the Science Advisor, U.S. Environmental Protection Agency (updated 18 June 2012). Available: http://www.epa.gov/raf/publications/benchmarkdose.htm [accessed 8 April 2014].
6. ICF International, Inc. BMDS Wizard [website]. Fairfax, VA:ICF International, Inc. (2014). Available: http://www.icfi.com/insights/products-and-tools/bmds-wizard [accessed 8 April 2014].
If you’re attending the American Public Health Association (APHA) 2016 Annual Meeting and Expo in Denver (October 30–November 2), stop by the NIEHS booth (#1214) in the Exhibition Hall. Children’s Health Editor Martha M. Dimes will be available to discuss EHP submissions, Children’s Health topics, and more.
EHP is pleased to launch its new Children’s Health page. This dynamic page will feature timely children’s health research and news as they are published in EHP as well as links to related material. The page includes its own “Search Children’s Health” function so visitors can search our full library of children’s health content by topic, author, or publication year and find exactly the information they need. Bookmark the page or access it via the “Featured Children’s Health” section on EHP’s home page. (more…)
EHP is proud to announce that “Polychlorinated Biphenyl and Organochlorine Pesticide Concentrations in Maternal Mid-Pregnancy Serum Samples: Association with Autism Spectrum Disorder and Intellectual Disability,” published in EHP on 23 August 2016, has been selected by the Children’s Environmental Health Network (CEHN) as its October 2016 Article of the Month. CEHN Article of the Month summaries discuss the potential policy implications of current children’s environmental health research. The CEHN summary can be viewed here.
Featured Children’s Health
Veronica A. Tinney, Jerad M. Denton, Lucy Sciallo-Tyler, and Jerome A. Paulson
Jerome A. Paulson and Claire L. Barnett
Kim G. Harley, Katherine Kogut, Daniel S. Madrigal, Maritza Cardenas, Irene A. Vera, Gonzalo Meza-Alfaro, Jianwen She, Qi Gavin, Rana Zahedi, Asa Bradman, Brenda Eskenazi, and Kimberly L. Parra
Rebecca Massa Nachman, Guangyun Mao, Xingyou Zhang, Xiumei Hong, Zhu Chen, Claire Sampankanpanich Soria, Huan He, Guoying Wang, Deanna Caruso, Colleen Pearson, Shyam Biswal, Barry Zuckerman, Marsha Wills-Karp, and Xiaobin Wang